Mark de Souza

Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA.

Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA.

Excelimmune, Inc. provides laboratory and biotechnology services. It is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. The firm’s next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens. The company was founded in 2006 by Quinton Y. Zondervan and Vincent W. Coljee and is headquartered in Lexington, MA.

PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA.

Myotherix, Inc. operates as a biopharmaceutical company focuses on the development of therapies. It focuses on the development of innovative therapies for patients suffering from Duchenne muscular dystrophy and other muscle disorders for which there are no treatments. The company was founded by John Kincaid and is headquartered in Emeryville, CA.

Willow Neuroscience, Inc. operates as a biotechnology company that wholesales pharmaceutical products. The company is headquartered in Emeryville, CA.

Flightpath Biosciences, Inc. operates as a biotechnology company. The firm develops novel therapeutics for the treatment of tick-borne diseases and acute and post treatment Lyme disease. The company was founded by Mark de Souza, Matthew Tindall, and Curtis Scribner in 2019 and is headquartered in Berkeley, CA.